"The U.S. Food and Drug Administration today approved Procysbi (cysteamine bitartrate) for the management of nephropathic cystinosis in children and adults. Procysbi was granted orphan product designation because it is intended to treat a rare dis"...
- Patient Information:
The patient should be instructed that, to ensure effectiveness of Zemplar therapy, it is important to adhere to a dietary regimen of calcium supplementation and phosphorus restriction. Appropriate types of phosphate-binding compounds may be needed to control serum phosphorus levels in patients with chronic kidney disease (CKD) Stage 5, but excessive use of aluminum containing compounds should be avoided (see WARNINGS). Patients should also be carefully informed about the symptoms of elevated calcium (see WARNINGS).
Last reviewed on RxList: 5/20/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Zemplar Injection Information
- Zemplar Injection Drug Interactions Center: paricalcitol iv
- Zemplar Injection Side Effects Center
- Zemplar Injection Overview including Precautions
- Zemplar Injection FDA Approved Prescribing Information including Dosage
Zemplar Injection - User Reviews
Zemplar Injection User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.